Bayer starts Phase II study of atrial fibrillation drug candidate
Bayer has started a Phase II study of an atrial fibrillation drug candidate.
Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
1 result loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Bayer has started a Phase II study of an atrial fibrillation drug candidate.